Matinas Biopharma (MTNB) Competitors $0.93 -0.02 (-2.09%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$0.93 0.00 (-0.23%) As of 07/25/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. MRKR, RVPH, RLMD, BLRX, LEXX, IXHL, RLYB, ASBP, VYNE, and PASGShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include MARKER THERAPEUTICS (MRKR), Reviva Pharmaceuticals (RVPH), Relmada Therapeutics (RLMD), BioLineRx (BLRX), Lexaria Bioscience (LEXX), Incannex Healthcare (IXHL), Rallybio (RLYB), Aspire Biopharma (ASBP), VYNE Therapeutics (VYNE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors MARKER THERAPEUTICS Reviva Pharmaceuticals Relmada Therapeutics BioLineRx Lexaria Bioscience Incannex Healthcare Rallybio Aspire Biopharma VYNE Therapeutics Passage Bio MARKER THERAPEUTICS (NASDAQ:MRKR) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Which has better valuation & earnings, MRKR or MTNB? MARKER THERAPEUTICS has higher revenue and earnings than Matinas Biopharma. MARKER THERAPEUTICS is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMARKER THERAPEUTICS$6.59M2.68-$10.73M-$1.33-1.17Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.24 Do insiders and institutionals hold more shares of MRKR or MTNB? 22.4% of MARKER THERAPEUTICS shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 14.5% of MARKER THERAPEUTICS shares are held by company insiders. Comparatively, 4.6% of Matinas Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is MRKR or MTNB more profitable? Matinas Biopharma has a net margin of 0.00% compared to MARKER THERAPEUTICS's net margin of -224.46%. MARKER THERAPEUTICS's return on equity of -101.87% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets MARKER THERAPEUTICS-224.46% -101.87% -83.02% Matinas Biopharma N/A -123.06%-94.28% Which has more volatility and risk, MRKR or MTNB? MARKER THERAPEUTICS has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Does the media favor MRKR or MTNB? In the previous week, MARKER THERAPEUTICS had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for MARKER THERAPEUTICS and 0 mentions for Matinas Biopharma. MARKER THERAPEUTICS's average media sentiment score of 0.94 beat Matinas Biopharma's score of 0.00 indicating that MARKER THERAPEUTICS is being referred to more favorably in the media. Company Overall Sentiment MARKER THERAPEUTICS Positive Matinas Biopharma Neutral Do analysts prefer MRKR or MTNB? MARKER THERAPEUTICS presently has a consensus price target of $13.17, suggesting a potential upside of 744.02%. Given MARKER THERAPEUTICS's stronger consensus rating and higher possible upside, equities research analysts clearly believe MARKER THERAPEUTICS is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MARKER THERAPEUTICS 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryMARKER THERAPEUTICS beats Matinas Biopharma on 14 of the 16 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.73M$786.26M$5.70B$21.04BDividend YieldN/A4.84%4.58%3.59%P/E Ratio-0.191.4428.4128.45Price / SalesN/A25.35432.3171.70Price / CashN/A19.5636.2222.92Price / Book0.216.918.674.68Net Income-$22.94M-$4.17M$3.25B$995.51M7 Day Performance-3.11%1.01%4.25%1.65%1 Month Performance-1.26%3.65%10.51%4.54%1 Year PerformanceN/A9.83%35.68%10.00% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.93-2.1%N/AN/A$4.73MN/A-0.1930MRKRMARKER THERAPEUTICS4.5775 of 5 stars$1.53-10.0%$13.17+760.6%-70.2%$19.24M$6.59M-1.1560Gap UpHigh Trading VolumeRVPHReviva Pharmaceuticals3.3771 of 5 stars$0.40-1.0%$9.00+2,176.8%-62.6%$19.16MN/A-0.505Positive NewsGap UpHigh Trading VolumeRLMDRelmada Therapeutics4.8099 of 5 stars$0.61+6.4%$5.00+714.3%-84.0%$19.15MN/A-0.2410Positive NewsGap DownBLRXBioLineRx2.7988 of 5 stars$4.36-2.5%$26.00+496.3%-87.8%$19.05M$28.94M-0.5040Positive NewsLEXXLexaria Bioscience2.2378 of 5 stars$0.95+1.0%$5.00+423.7%-68.3%$18.49M$460K-1.427IXHLIncannex Healthcare0.7365 of 5 stars$0.82+34.4%N/A-51.4%$17.95M$10K-0.683News CoverageGap DownHigh Trading VolumeRLYBRallybio2.8594 of 5 stars$0.46+7.5%$10.00+2,063.1%-62.5%$17.89M$640K-0.4240Positive NewsASBPAspire BiopharmaN/A$0.41+14.1%N/AN/A$17.73MN/A0.00N/ANews CoverageAnalyst DowngradeGap DownVYNEVYNE Therapeutics2.934 of 5 stars$1.21+4.3%$6.25+416.5%-30.5%$17.64M$500K-1.2230High Trading VolumePASGPassage Bio3.3846 of 5 stars$5.27-5.2%$150.00+2,746.3%-57.7%$17.35MN/A-0.26130News CoveragePositive NewsInsider TradeGap UpHigh Trading Volume Related Companies and Tools Related Companies MRKR Alternatives RVPH Alternatives RLMD Alternatives BLRX Alternatives LEXX Alternatives IXHL Alternatives RLYB Alternatives ASBP Alternatives VYNE Alternatives PASG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
